Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Researchs GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and published earlier this year in JAMA Internal Medicine
Individuals with SMIs experience premature and excess mortality, with years of life lost often estimated between 5 and 25 years, largely due to earlier onset and substantially higher rates of CVD
Transl Res
Pharmacies that get ahead of this now, by asking better questions and anticipating what patients arent saying, will be the ones that stay essential in the next phase of care.
US$ 22.98
/assets/images/provider/photos/2826746.png)
US$ 23.85
US$ 22.00
US$ 21.62
